Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) closed at $1.24 in the last session, up 12.73% from day before closing price of $1.10. In other words, the price has increased by $12.73 from its previous closing price. On the day, 0.78 million shares were traded.
Ratios:
We take a closer look at BCLI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.21 and its Current Ratio is at 0.21.
Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 01 ’24 when Lebovits Chaim bought 1,836 shares for $3.43 per share. The transaction valued at 6,292 led to the insider holds 80,960 shares of the business.
Lebovits Chaim bought 22,000 shares of BCLI for $5,016 on Sep 30 ’24. The President & CEO now owns 1,186,865 shares after completing the transaction at $0.23 per share. On Jul 19 ’24, another insider, Dagher Ibrahim B., who serves as the Chief Medical Officer of the company, sold 63,000 shares for $0.35 each. As a result, the insider received 22,069 and left with 0 shares of the company.
Stock Price History:
Over the past 52 weeks, BCLI has reached a high of $8.09, while it has fallen to a 52-week low of $0.72. The 50-Day Moving Average of the stock is 12.32%, while the 200-Day Moving Average is calculated to be -33.86%.
Shares Statistics:
A total of 7.91M shares are outstanding, with a floating share count of 6.17M. Insiders hold about 22.32% of the company’s shares, while institutions hold 12.89% stake in the company.
